항염증 치료제 시장 규모, 점유율, 성장 분석 : 약제 클래스별, 적응증별, 용도별, 유통경로별, 지역별 - 업계 예측(2025-2032년)

Global Anti-Inflammatory Therapeutics Market size was valued at USD 102.4 billion in 2023 and is poised to grow from USD 107.32 billion in 2024 to USD 156.15 billion by 2032, growing at a CAGR of 4.8% during the forecast period (2025-2032).

The global market for anti-inflammatory therapeutics is experiencing significant growth driven by the rising prevalence of autoimmune and chronic inflammatory diseases like rheumatoid arthritis, asthma, and inflammatory bowel disease (IBD). The persistent burden on healthcare systems underscores the need for innovative treatment options. Biologics and targeted therapies have significantly enhanced patient outcomes, while the introduction of biosimilars promotes competition and decreases costs, making advanced treatments more accessible. As the aging population continues to experience chronic inflammation, demand for these therapies is expected to rise. Furthermore, numerous pipeline biologics targeting interleukin pathways indicate a promising future, paving the way for advancements in precision medicine and solidifying long-term market potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Anti-Inflammatory Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Anti-Inflammatory Therapeutics Market Segments Analysis

Global Anti-Inflammatory Therapeutics Market is segmented by Drug Class, Indication, Application, Distribution Channel and region. Based on Drug Class, the market is segmented into Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids. Based on Indication, the market is segmented into Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis and Inflammatory Bowel Disease. Based on Application, the market is segmented into Autoimmune, Inflammatory Diseases and Respiratory Diseases. Based on Distribution Channel, the market is segmented into Hospital Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Anti-Inflammatory Therapeutics Market

The Global Anti-Inflammatory Therapeutics market is driven by the increasing prevalence of autoimmune and chronic inflammatory diseases such as inflammatory bowel disease, psoriasis, asthma, and rheumatoid arthritis. The significant rise in the number of individuals affected by conditions like arthritis has led to heightened demand for advanced therapeutic options. This growing patient population underscores the necessity for effective treatments, fueling the acceptance and utilization of biologics and biosimilars on a global scale. As awareness of these complex conditions expands, the market responds with innovative solutions aimed at addressing the diverse needs of patients seeking relief from persistent inflammatory ailments.

Restraints in the Global Anti-Inflammatory Therapeutics Market

The high cost of biologic treatments presents a significant barrier to access for patients, particularly in low- and middle-income nations. Biologics like Humira can reach annual costs of up to USD 72,000 for a single patient, making them prohibitively expensive for many individuals. This affordability challenge persists even for biosimilars, which are often intended to be more cost-effective alternatives. Additionally, discrepancies in insurance coverage and protracted reimbursement processes exacerbate the situation, limiting patient access to necessary care across various global regions. Consequently, these financial and systemic hurdles hinder the overall effectiveness of anti-inflammatory therapeutics on a global scale.

Market Trends of the Global Anti-Inflammatory Therapeutics Market

The Global Anti-Inflammatory Therapeutics market is experiencing a significant shift towards the development of targeted biologics and sophisticated small molecules. Innovations such as IL-23 inhibitors, JAK inhibitors, and FcRn-targeting antibodies are increasingly replacing traditional broad-spectrum immunosuppressants. This trend reflects a strategic expansion of therapeutic applications, moving from niche autoimmune disorders to common conditions like ulcerative colitis, enhancing therapeutic efficacy while minimizing side effects. As blockbuster drugs face intensified competition from generics and biosimilars, this diversification not only elevates the market potential but also drives companies to deliver more specialized and commercially valuable treatment options.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Anti-Inflammatory Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Anti-Inflammatory Biologics
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Corticosteroids

Global Anti-Inflammatory Therapeutics Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Arthritis
• Respiratory Diseases
• Multiple Sclerosis
• Psoriasis
• Inflammatory Bowel Disease

Global Anti-Inflammatory Therapeutics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Autoimmune
• Inflammatory Diseases
• Respiratory Diseases

Global Anti-Inflammatory Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy

Global Anti-Inflammatory Therapeutics Market Size & CAGR (2025-2032)

• North America (Drug Class, Indication, Application, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Indication, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Indication, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Indication, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Indication, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK/Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK (GlaxoSmithKline) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations